Autolus Therapeutics to Participate in the Jefferies Global Healthcare Conference in London
Autolus Therapeutics (Nasdaq: AUTL) will participate in the Jefferies Global Healthcare Conference in London.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Autolus Therapeutics (Nasdaq: AUTL) will participate in the Jefferies Global Healthcare Conference in London. CEO Dr. Christian Itin will appear in a fireside chat on Tuesday, November 18, 2025 at 7:30 AM EST / 12:30 PM GMT. A live webcast will be available on the company’s Events page and a replay will be archived on the website for 90 days after the presentation.
The presentation covers company updates and investor engagement; webcast access is via the company investor relations site.
Details
News Market Reaction – AUTL
On Nov 14, the first trading day after this news, AUTL closed 7.03% above the previous close.
Data tracked by StockTitan Argus for the Nov 14 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
LONDON and GAITHERSBURG, Md., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announces that the Company will participate in the Jefferies Global Healthcare Conference in London.
Autolus Chief Executive Officer Dr. Christian Itin will present in a Fireside Chat on Tuesday, November 18, 2025 at 7:30am EST / 12:30pm GMT.
A webcast of the fireside chat will be available on the “Events” page in the “Investor Relations & Media” section of the Company’s website at https://www.autolus.com/investor-relations-media/events/. A replay of the webcast will be archived on the Company’s website for 90 days following the presentation.
About Autolus Therapeutics plc
Autolus Therapeutics plc (Nasdaq: AUTL) is an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation T cell therapies and candidates for the treatment of cancer and autoimmune disease. Using a broad suite of proprietary and modular T cell programming technologies, Autolus is engineering precisely targeted and controlled T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and eliminate these cells. Autolus has a marketed therapy, AUCATZYL®, and a pipeline of product candidates in development for the treatment of hematological malignancies, solid tumors and autoimmune diseases. For more information, please visit www.autolus.com.
Contact:
Amanda Cray
+1 617-967-0207
a.cray@autolus.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.